Bob Bradway, Amgen CEO (Stephen Lam/Reuters)
April 28, 2023 07:22 AM EDT
R&D

Am­gen bows out of PhI­Ib tri­als test­ing bis­pe­cif­ic, fu­sion pro­tein for lu­pus

Amber Tong

In a set­back to the grow­ing field of sys­temic lu­pus ery­the­mato­sus drug de­vel­op­ment, Am­gen is bow­ing out of two Phase IIb tri­als af­ter de­cid­ing its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times